BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fuji
Deloitte
Queensland Health
Accenture
Teva
Harvard Business School
Colorcon
UBS
AstraZeneca

Generated: January 17, 2018

DrugPatentWatch Database Preview

PROSTIN E2 Drug Profile

« Back to Dashboard

When do Prostin E2 patents expire, and what generic alternatives are available?

Prostin E2 is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in PROSTIN E2 is dinoprostone. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dinoprostone profile page.
Drug patent expirations by year for PROSTIN E2
Pharmacology for PROSTIN E2
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Medical Subject Heading (MeSH) Categories for PROSTIN E2

US Patents and Regulatory Information for PROSTIN E2

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn PROSTIN E2 dinoprostone SUPPOSITORY;VAGINAL 017810-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PROSTIN E2

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn PROSTIN E2 dinoprostone SUPPOSITORY;VAGINAL 017810-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Pharmacia And Upjohn PROSTIN E2 dinoprostone SUPPOSITORY;VAGINAL 017810-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
Mallinckrodt
UBS
US Department of Justice
Accenture
Covington
Daiichi Sankyo
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot